The stock of Flex Pharma Inc (NASDAQ:FLKS) is a huge mover today! The stock decreased 4.15% or $0.29 during the last trading session, hitting $6.69. About 62,257 shares traded hands. Flex Pharma Inc (NASDAQ:FLKS) has declined 41.54% since April 13, 2016 and is downtrending. It has underperformed by 45.47% the S&P500.
The move comes after 7 months negative chart setup for the $119.88 million company. It was reported on Nov, 15 by Barchart.com. We have $5.95 PT which if reached, will make NASDAQ:FLKS worth $13.19M less.
Flex Pharma Inc (NASDAQ:FLKS) Ratings Coverage
Out of 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Flex Pharma has been the topic of 3 analyst reports since August 21, 2015 according to StockzIntelligence Inc. The company was downgraded on Friday, October 14 by Cantor Fitzgerald. The company was upgraded on Wednesday, September 2 by Zacks. Zacks downgraded the stock to “Hold” rating in Friday, August 21 report.
According to Zacks Investment Research, “Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.”
More notable recent Flex Pharma Inc (NASDAQ:FLKS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on January 28, 2015, also Quotes.Wsj.com with their article: “News Flex Pharma Inc.FLKS” published on January 24, 2015, Streetinsider.com published: “Form 8-K Flex Pharma, Inc. For: Nov 15” on November 15, 2016. More interesting news about Flex Pharma Inc (NASDAQ:FLKS) were released by: Bostonglobe.com and their article: “Boston’s Flex Pharma raises $86.4 million in IPO” published on January 29, 2015 as well as Businesswire.com‘s news article titled: “Flex Pharma Announces FLX-787 as Clinical Drug Candidate” with publication date: November 10, 2015.
FLKS Company Profile
Flex Pharma, Inc., incorporated on February 26, 2014, is a biotechnology firm that is developing treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Firm operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s product candidates are based on the mechanism of action described as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, is translated into a neuronal sensory signal that produces a beneficial effect. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing products using TRP activators.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.